You are here: Industry Insights > Market News > Alkem’s St Louis facility gets two observations from US FDA

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Alkem’s St Louis facility gets two observations from US FDA

expresspharmaJune 21, 2021

Tag: FDA , Alkem , facility

Favorites

Alkem Laboratories informed that the US FDA has issued Form 483 with two observations for its manufacturing facility located in St Louis, US. The US FDA had conducted an inspection of the company’s manufacturing facility from 14-18, June 2021.

The company also informed that it will submit to US FDA within the stipulated timeline, a detailed response to close out all the observations associated with this inspection.

Previous:Study shows corticosteroids may be effective in treating COVID-19 complications in children

Next:Israeli scientists find promising target for breast cancer and other cancer therapeutics

New CRO Focused on Cannabis-based Drug Trials Launched

Biotech NewswireMay 23, 2024

Cannovation Clinical Research Partners takes a holistic approach to assist businesses throughout the entire product lifecycle, encompassing product development, commercialization, and launch phases.

InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

PharmaSourcesMay 21, 2024

Selection of Commercial Models for Innovative Drugs

PharmaSourcesMay 21, 2024

Alkem’s St Louis facility gets two observations from US FDA | Pharmasources.com

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

Biotech NewswireMay 17, 2024

The expanded collaboration includes increasing adoption of the NVIDIA Clara suite of AI-powered computing platforms, software, and services in the Sartorius ecosystem.

Alkem’s St Louis facility gets two observations from US FDA

Related News

New CRO Focused on Cannabis-based Drug Trials Launched

InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

Selection of Commercial Models for Innovative Drugs

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

You may like